Effect of obesity, dyslipidemia, and diabetes on trastuzumab-related cardiotoxicity in breast cancer

P Kosalka, C Johnson, M Turek, J Sulpher, A Law… - Current …, 2019 - mdpi.com
Background: Clinical trials have demonstrated an increased risk of cardiotoxicity in patients
with breast cancer (BCA) receiving trastuzumab-based therapy. Diabetes, dyslipidemia, and …
被引用次数：41 相关文章
[PDF] semanticscholar.org

[PDF][PDF] Effect of obesity, dyslipidemia, and diabetes on trastuzumab-related cardiotoxicity in breast cancer

P Kosalka, C Johnson, M Turek, J Sulpher… - Current …, 2019 - pdfs.semanticscholar.org
Background Clinical trials have demonstrated an increased risk of cardiotoxicity in patients
with breast cancer (bca) receiving trastuzumab-based therapy. Diabetes, dyslipidemia, and …
[HTML] nih.gov

[HTML][HTML] Effect of obesity, dyslipidemia, and diabetes on trastuzumab-related cardiotoxicity in breast cancer

P Kosalka, C Johnson, M Turek, J Sulpher… - Current …, 2019 - ncbi.nlm.nih.gov
Background Clinical trials have demonstrated an increased risk of cardiotoxicity in patients
with breast cancer (bc a) receiving trastuzumab-based therapy. Diabetes, dyslipidemia, and …

Effect of obesity, dyslipidemia, and diabetes on trastuzumab-related cardiotoxicity in breast cancer.

P Kosalka, C Johnson, M Turek, J Sulpher… - Current Oncology …, 2019 - europepmc.org
Background Clinical trials have demonstrated an increased risk of cardiotoxicity in patients
with breast cancer (bca) receiving trastuzumab-based therapy. Diabetes, dyslipidemia, and …

Effect of obesity, dyslipidemia, and diabetes on trastuzumab-related cardiotoxicity in breast cancer.

P Kosalka, C Johnson, M Turek, J Sulpher… - Current …, 2019 - search.ebscohost.com
Background Clinical trials have demonstrated an increased risk of cardiotoxicity in patients
with breast cancer (bca) receiving trastuzumab-based therapy. Diabetes, dyslipidemia, and …

Effect of obesity, dyslipidemia, and diabetes on trastuzumab-related cardiotoxicity in breast cancer

P Kosalka, C Johnson, M Turek… - Current oncology …, 2019 - pubmed.ncbi.nlm.nih.gov
Background Clinical trials have demonstrated an increased risk of cardiotoxicity in patients
with breast cancer (bca) receiving trastuzumab-based therapy. Diabetes, dyslipidemia, and …

Effect of obesity, dyslipidemia, and diabetes on trastuzumab-related cardiotoxicity in breast cancer.

P Kosalka, C Johnson, M Turek, J Sulpher… - Current Oncology …, 2019 - europepmc.org
Background Clinical trials have demonstrated an increased risk of cardiotoxicity in patients
with breast cancer (bca) receiving trastuzumab-based therapy. Diabetes, dyslipidemia, and …